Myalept (metreleptin) prior authorization and medical necessity
Customize your policy alerts
Sign up for all UnitedHealthcare policy alerts
Know when UnitedHealthcare releases new policies or updates existing guidance.
Monitor payer policy activity
Defines UnitedHealthcare prior authorization and medical necessity criteria for Myalept (metreleptin) use to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; applies to clinicians and payers managing coverage decisions.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Therapy — Covered when ALL of the following are met.
Covered when ALL of the following are met:
Optimized therapy refers to maximum tolerated doses
Reauthorization / Continued Therapy — Reauthorization covered when ALL of the following are met.
Reauthorization covered when ALL of the following are met:
The policy excludes use of Myalept (metreleptin) in settings where safety and effectiveness have not been established. Specifically, Myalept should not be used for partial lipodystrophy, for treatment of liver disease including nonalcoholic steatohepatitis (NASH), or for HIV-related lipodystrophy. Additionally, Myalept is not indicated for patients with metabolic disease in the absence of documented generalized lipodystrophy. These scope limitations reflect the lack of established benefit and the elevated risks in non-generalized lipodystrophy populations.
Because Myalept carries risks related to development of neutralizing anti-metreleptin antibodies and lymphoma, access is restricted: Myalept is available only through the Myalept REMS program. Requests for coverage for excluded indications are at high risk for denial under this policy.
Myalept is not indicated for treatment of complications of partial lipodystrophy or for patients with HIV-related lipodystrophy. The policy also states Myalept is not indicated for use solely for metabolic disease when there is no concurrent evidence of generalized lipodystrophy. These uses are considered unsupported by established safety and effectiveness and would be considered not medically necessary under this policy.
Because of safety concerns including the potential for neutralizing antibodies and lymphoma, Myalept is distributed only through a restricted program (the Myalept REMS), which further limits off-label or non-indicated use.
Clinical Thresholds and Codes
Prior Authorization, Documentation, and Required Therapies
Prior authorization required; 12-month approvals
Prior authorization is required. Initial approval is granted only when all listed coverage criteria are met (diagnosis of congenital or acquired generalized lipodystrophy with leptin deficiency; Myalept used as an adjunct to diet modification; prescribed by an endocrinologist; and metabolic eligibility criteria). Authorization will be issued for 12 months; reauthorization is granted for 12 months when reauthorization criteria are met.
- Initial approval requires all Initial Authorization criteria in the policy to be satisfied.
- Authorization duration: 12 months for initial and reauthorization.
Required prior/concurrent therapies before Myalept
Before initiating Myalept for hyperglycemia, the patient must have tried dietary intervention and optimized insulin therapy at maximum tolerated doses. Before initiating Myalept for hypertriglyceridemia, the patient must have tried dietary intervention and optimized therapy with at least two triglyceride‑lowering agents from different classes at maximum tolerated doses.
- Hyperglycemia pathway: dietary intervention AND optimized insulin therapy at maximum tolerated doses (HgbA1C > 7.0 threshold applies).
- Hypertriglyceridemia pathway: dietary intervention AND optimized therapy with ≥2 triglyceride‑lowering agents from different classes (e.g., fibrates, statins) at maximum tolerated doses (TG > 200 threshold applies).
Required documentation for initial authorization and reauthorization
Documentation must demonstrate diagnosis of congenital or acquired generalized lipodystrophy associated with leptin deficiency; that Myalept is being used as an adjunct to diet modification; and that the prescriber is an endocrinologist. For initial requests, include evidence of metabolic eligibility (either persistent hyperglycemia with HgbA1C > 7.0 despite dietary intervention and optimized insulin therapy at maximum tolerated doses OR persistent TG > 200 despite dietary intervention and optimized therapy with at least two triglyceride‑lowering agents from different classes at maximum tolerated doses). For reauthorization, include documentation of positive clinical response to Myalept in addition to continued adjunctive diet use and endocrinologist prescribing.
- Initial documentation: diagnosis of congenital or acquired generalized lipodystrophy with leptin deficiency; evidence of dietary intervention; prescriber specialty (endocrinologist); metabolic data showing HgbA1C > 7.0 despite interventions OR TG > 200 despite interventions with ≥2 agents.
- Reauthorization documentation: evidence of positive clinical response, continued adjunct to diet, and endocrinologist prescriber.
Denial risk for non‑qualifying diagnosis or use
Requests lacking the covered diagnosis or meeting excluded uses are at risk for denial. Specifically, requests for diagnoses other than congenital or acquired generalized lipodystrophy associated with leptin deficiency, or use for partial lipodystrophy, HIV‑related lipodystrophy, liver disease (including NASH), or metabolic disease without evidence of generalized lipodystrophy may be denied.
- Denial risk if prescriber is not an endocrinologist or if Myalept is not documented as an adjunct to diet modification.
- Denial risk for use in partial lipodystrophy, HIV‑related lipodystrophy, liver disease (including NASH), or metabolic disease without generalized lipodystrophy.
Key Definitions
Background and Drug Information
Myalept (metreleptin) is a recombinant leptin analog indicated as an adjunct to diet as replacement therapy to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The therapy is intended to address metabolic complications related to leptin deficiency in this specific population.
The policy emphasizes that Myalept’s safety and effectiveness have not been established for partial lipodystrophy, liver disease including nonalcoholic steatohepatitis (NASH), HIV-related lipodystrophy, or for metabolic disease without evidence of generalized lipodystrophy. Due to risks such as development of neutralizing anti-metreleptin antibodies and lymphoma, Myalept is available only through the Myalept REMS restricted program.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.